On Friday, the FDA approved Checkpoint Therapeutics, Inc.’s (NASDAQ:CKPT) Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...
Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the ...
“Today’s FDA approval of Unloxcyt – the first marketing approval for our company…This approval marks Checkpoint’s transformation to a commercial-stage company, with the opportunity to ...
JERUSALEM, Dec 16 (Reuters) - Check Point Software Technologies (CHKP.O), opens new tab said on Monday that Nadav Zafrir has taken over as chief executive, replacing Gil Shwed who had been CEO for ...